Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies.
Journal
JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
entrez:
15
9
2022
pubmed:
16
9
2022
medline:
20
9
2022
Statut:
ppublish
Résumé
The prognosis of patients with non-small-cell lung cancer (NSCLC), traditionally determined by anatomic histology and TNM staging, neglects the biological features of the tumor that may be important in determining patient outcome and guiding therapeutic interventions. Identifying patients with NSCLC at increased risk of recurrence after curative-intent surgery remains an important unmet need so that known effective adjuvant treatments can be offered to those at highest risk of recurrence. Relative gene expression level in the primary tumor and normal bronchial tissues was used to retrospectively assess their association with disease-free survival (DFS) in a cohort of 120 patients with NSCLC who underwent curative-intent surgery. Low versus high Digital Display Precision Predictor (DDPP) score (a measure of relative gene expression) was significantly associated with shorter DFS (highest recurrence risk; TNM stage, DDPP score, and immune competence status of normal lung are independent prognostic factors in multivariate analysis. Our findings open new avenues for prospective prognostic assessment and treatment assignment on the basis of transcriptomic profiling of tumor and normal lung tissue in patients with NSCLC.
Identifiants
pubmed: 36108261
doi: 10.1200/PO.22.00072
pmc: PMC9489166
doi:
Substances chimiques
B7-H1 Antigen
0
CTLA-4 Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2200072Déclaration de conflit d'intérêts
<b>Vladimir Lazar</b><b>Patents, Royalties, Other Intellectual Property:</b> I am inventor on patentes filed by WIN Consortium I do not receive money <b>Nicolas Girard</b><b>Employment:</b> AstraZeneca (I)<b>Consulting or Advisory Role:</b> Roche, Lilly, AstraZeneca, Novartis, Pfizer, Bristol Myers Squibb, MSD, Takeda, Janssen, Sanofi, Amgen<b>Research Funding:</b> Roche (Inst), AstraZeneca (Inst), BMS (Inst)<b>Travel, Accommodations, Expenses:</b> Roche <b>Eric Raymond</b><b>Employment:</b> Genoscience Pharma, SCOR, StromaCare, Onward Therapeutics<b>Leadership:</b> AFR-Oncology<b>Stock and Other Ownership Interests:</b> Neuronax, Oncoethix, Genoscience Pharma, SCOR<b>Consulting or Advisory Role:</b> Lilly, Pfizer, Merck Serono, PharmaEngine, Novartis/lpsen, Celgene <b>Jean-François Martini</b><b>Employment:</b> Pfizer<b>Stock and Other Ownership Interests:</b> Pfizer <b>Susan Galbraith</b><b>Employment:</b> AstraZeneca<b>Leadership:</b> BB Biotech Ventures<b>Stock and Other Ownership Interests:</b> AstraZeneca <b>Benjamin Solomon</b><b>Consulting or Advisory Role:</b> Bayer<b>Research Funding:</b> AstraZeneca/Merck (Inst)<b>Open Payments Link:</b> https://openpaymentsdata.cms.gov/physician/358846 <b>Hovav Nechushtan</b><b>Research Funding:</b> AstraZeneca (Inst), Spectrum Pharmaceuticals (Inst), Lilly (Inst), Merck KGaA (Inst)<b>Uncompensated Relationships:</b> MSD <b>Amir Onn</b><b>Honoraria:</b> Boehringer Ingelheim, Roche, MSD, Amgen<b>Consulting or Advisory Role:</b> Boehringer Ingelheim, MSD<b>Speakers' Bureau:</b> AstraZeneca <b>Raanan Berger</b><b>Stock and Other Ownership Interests:</b> Belong<b>Honoraria:</b> Bristol Myers Squibb, Roche Israel, AstraZeneca, Pfizer, MSD<b>Consulting or Advisory Role:</b> Belong, MSD Oncology, BMS<b>Speakers' Bureau:</b> Mitra Biotech, BMS, MSD Oncology<b>Travel, Accommodations, Expenses:</b> Mitra Biotech, Bristol Myers Squibb, MSD, AstraZeneca <b>Sadakatsu Ikeda</b><b>Honoraria:</b> Chugai Pharma, Novartis, AstraZeneca, Taiho Pharmaceutical, Guardant Health, Bristol Myers Squibb-Ono Pharmaceutical, MSD, ACT Genomics, Roche, Canon Medical System, ACT Med<b>Consulting or Advisory Role:</b> Genodive Pharma (Inst)<b>Research Funding:</b> ACT Genomics (Inst), Hitachi (Inst), Canon Medical System (Inst) <b>Ulrik Lassen</b><b>Honoraria:</b> Bayer, Pfizer, Novartis<b>Consulting or Advisory Role:</b> Bayer, Pfizer<b>Research Funding:</b> BMS (Inst), Roche (Inst), Pfizer (Inst), GlaxoSmithKline (Inst), Incyte (Inst), Lilly (Inst) <b>Enriqueta Felip</b><b>Consulting or Advisory Role:</b> Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Lilly, GlaxoSmithKline, Janssen, Merck Serono, Novartis, Pfizer, Sanofi, Takeda, Peptomyc, Daiichi Sankyo Europe GmbH, F. Hoffmann La Roche, Merck Sharp & Dohme<b>Speakers’ Bureau:</b> AstraZeneca, Bristol Myers Squibb, Lilly, Medscape, Merck Sharp & Dohme, PeerVoice, Pfizer, Takeda, Amgen, F. Hoffmann La Roche, Janssen, Medical Trends, Merck Serono, Sanofi, TouchONCOLOGY<b>Research Funding:</b> Merck (Inst), Merck KGaA (Inst)<b>Other Relationship:</b> GRiFOLS <b>Josep Tabernero</b><b>Stock and Other Ownership Interests:</b> Oniria Therapeutics<b>Consulting or Advisory Role:</b> Bayer, Boehringer Ingelheim, Lilly, MSD, Merck Serono, Novartis, Sanofi, Taiho Pharmaceutical, Peptomyc, Chugai Pharma, Pfizer, Seattle Genetics, Array BioPharma, AstraZeneca, Genentech, Menarini, Servier, HalioDx, F. Hoffmann La Roche, Mirati Therapeutics, Pierre Fabre, Tessa Therapeutics, TheraMyc, Daiichi Sankyo, Samsung Bioepis, IQvia, Ikena Oncology, Merus, Neophore, Orion Biotechnology, Hutchison MediPharma, Scandion Oncology, Ona Therapeutics, Sotio, Inspirna, Scorpion Therapeutics<b>Other Relationship:</b> Imedex, Medscape, MJH Life Sciences, Peerview, Physicans' Education Resource <b>Alan Spatz</b><b>Consulting or Advisory Role:</b> Janssen, Bristol Myers Squibb, Pfizer/EMD Serono, Merck, Roche, AstraZeneca, Novartis, Bayer, AbbVie<b>Research Funding:</b> Merck (Inst), Bristol Myers Squibb (Inst) <b>C.S. Pramesh</b><b>Stock and Other Ownership Interests:</b> Aurobindo <b>Philippe Girard</b><b>Honoraria:</b> Bayer, LEO Pharma, BMS/Pfizer<b>Consulting or Advisory Role:</b> LEO Pharma, Bayer, BMS/Pfizer<b>Travel, Accommodations, Expenses:</b> Bayer, LEO Pharma, BMS/Pfizer <b>Jean-Yves Blay</b><b>Leadership:</b> Innate Pharma<b>Honoraria:</b> Roche, AstraZeneca, PharmaMar, MSD, BMS, Bayer, Ignyta, Deciphera<b>Consulting or Advisory Role:</b> Roche, Pharmamar, Deciphera, Blueprint Medicines, Bayer, Karyopharm Therapeutics<b>Research Funding:</b> GlaxoSmithKline (Inst), Pharmamar (Inst), Novartis (Inst), Bayer (Inst), Roche (Inst), BMS (Inst), MSD (Inst), Deciphera (Inst), AstraZeneca (Inst), OSE Pharma (Inst)<b>Travel, Accommodations, Expenses:</b> Roche <b>Angel Porgador</b><b>Stock and Other Ownership Interests:</b> Pooldi<b>Consulting or Advisory Role:</b> PiNK<b>Patents, Royalties, Other Intellectual Property:</b> Ben-Gurion University, Israel, several patents <b>Eitan Rubin</b><b>Stock and Other Ownership Interests:</b> Pfizer <b>Razelle Kurzrock</b><b>Leadership:</b> CureMatch, CureMetrix<b>Stock and Other Ownership Interests:</b> CureMatch, IDbyDNA, CureMetrix<b>Honoraria:</b> Roche, EUSA Pharma, NeoGenomics Laboratories, Biocom, NeoMed, Advanced Therapeutics, LEK, AACR, Chugai Pharma USA, Wiley, Merck, Pfizer, Meyer Consulting, Foundation Medicine, Turning Point Therapeutics, Bicara Therapeutics<b>Consulting or Advisory Role:</b> Actuate Therapeutics, Loxo, XBiotech, NeoMed, Roche, Gaido, Soluventis, Pfizer, Merck, Turning Point Therapeutics, TD2/Volastra, Bicara Therapeutics, AstraZeneca, Biological Dynamics, Daiichi Sankyo, Eisai, EOM Pharmaceuticals, lylon, Prosperdtx<b>Speakers' Bureau:</b> Roche<b>Research Funding:</b> Guardant Health (Inst), Sequenom (Inst), Merck Serono (Inst), Genentech (Inst), Pfizer (Inst), Foundation Medicine (Inst), Incyte (Inst), Konica Minolta (Inst), Grifols (Inst), OmniSeq (Inst), Debiopharm Group (Inst), Boehringer Ingelheim (Inst), Top Alliance BioScience (Inst), Takeda (Isnt), Medlmmune (Inst), Biological Dynamics (Inst)<b>Travel, Accommodations, Expenses:</b> Roche, EUSA Pharma, NeoGenomics Laboratories, Biocom, NeoMed, Advanced Therapeutics, LEK, AACR, Chugai Pharma USA, Wiley <b>Richard L. Schilsky</b><b>Leadership:</b> Clarified Precision Medicine<b>Stock and Other Ownership Interests:</b> EQRx<b>Consulting or Advisory Role:</b> Cellworks, Scandion Oncology, Bryologyx, IIIumina, EQRx, Syapse, ZephyrAI<b>Research Funding:</b> AstraZeneca (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Genentech/Roche (Inst), Lilly (Inst), Merck (Inst), Pfizer (Inst), Boehringer Ingelheim (Inst), Seattle Genetics (Inst)<b>Open Payments Link:</b> https://openpaymentsdata.cms.gov/physician/I138818/summaryNo other potential conflicts of interest were reported.
Références
PLoS Med. 2005 Aug;2(8):e124
pubmed: 16060722
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
N Engl J Med. 2018 Jul 12;379(2):111-121
pubmed: 29860917
J Clin Oncol. 2017 Jun 20;35(18):2018-2027
pubmed: 28453411
Cancer Discov. 2021 Apr;11(4):838-857
pubmed: 33811120
J Clin Oncol. 2010 Oct 10;28(29):4417-24
pubmed: 20823422
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Transl Lung Cancer Res. 2015 Apr;4(2):191-7
pubmed: 25870801
Clin Cancer Res. 2020 Apr 1;26(7):1656-1666
pubmed: 31772122
J Thorac Oncol. 2009 Jul;4(7):792-801
pubmed: 19458556
Sci Transl Med. 2010 Jan 13;2(14):14ps2
pubmed: 20371465
Ann Thorac Cardiovasc Surg. 2007 Apr;13(2):73-7
pubmed: 17505412
Nat Rev Genet. 2004 Mar;5(3):229-37
pubmed: 14970825
BMC Med Genomics. 2013 Dec 03;6:53
pubmed: 24299561
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
NPJ Precis Oncol. 2021 Apr 28;5(1):33
pubmed: 33911192
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
J Natl Cancer Inst. 2010 Apr 7;102(7):464-74
pubmed: 20233996
Chest. 2009 Jul;136(1):260-271
pubmed: 19584208
J Clin Oncol. 2010 Jan 1;28(1):35-42
pubmed: 19933916
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738